0001415889-24-009364.txt : 20240328
0001415889-24-009364.hdr.sgml : 20240328
20240328180013
ACCESSION NUMBER: 0001415889-24-009364
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240327
FILED AS OF DATE: 20240328
DATE AS OF CHANGE: 20240328
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dake Benjamin T
CENTRAL INDEX KEY: 0001869248
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 24800965
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-03282024_060301.xml
X0508
4
2024-03-27
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001869248
Dake Benjamin T
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
SEE REMARKS
1
Common Stock
2024-03-27
4
M
0
11068
10.61
A
12359
D
Common Stock
2024-03-27
4
S
0
11068
27.9652
D
1291
D
Stock Option (Right to Buy)
10.61
2024-03-27
4
M
0
11068
0
D
2031-12-13
Common Stock
11068
29000
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.
Officer Title: President, Chief Operating Officer and Secretary
/s/ George A. Eldridge, Attorney-in-Fact
2024-03-28